BIOMAT Database Logo BIOMAT Database Logo

Rapid, reproducible pain relief with [131I]iodine-meta-iodobenzylguanidine in a boy with disseminated neuroblastoma. 1995

Jan-Erik Westlin, and Henry Letocha, and Åke Jakobson, and Peter Strang, and Ulla Martinsson, and Sten Nilsson
Section of Nuclear Medicine at the Akademiska Sjukhuset, University Hospital, SE-751 85 Uppsala, Sweden Department of Oncology, Akademiska Sjukhuset, University Hospital, SE-751 85 Uppsala, Sweden The PET Centre, University Hospital, Uppsala University, Uppsala SE-751 85, Sweden Department of Pediatrics, The Children's Hospital, University Hospital, Uppsala University, Uppsala SE-751 85, Sweden.

[131I]Iodine-meta-iodobenzylguanidine ([131I]MIBG) is a radioactively labelled substance which is incorporated intracellularly by cells with neuroendocrine differentiation and used in the treatment of neuroendocrine malignancies. The agent was systemically administered on three occasions during a period of 16 weeks to a 4-year-old boy afflicted with disseminated neuroblastoma and suffering from severe pain caused by the disease. Initially, during the weeks immediately prior to radionuclide therapy, the boy required continuous intravenous infusions of morphine. On the 3rd day after each treatment, morphine administration could be discontinued and the boy appeared to be pain free. His appetite returned to normal and he became more mobile. The therapy had a good effect on his pain on each of the three occasions. Recurrent side effects were thrombocytopenia and cystitis. It is concluded that treatment with systemic radiotherapy in the form of [131I]MIBG was easy to perform and effective in this case of disseminated neuroblastoma and illustrates that this primary therapy can be used for palliative purposes.

UI MeSH Term Description Entries
D007462 Iodobenzenes Any derivative of BENZENE that contains IODINE.
D008297 Male Males
D009447 Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51) Neuroblastomas
D011859 Radiography Examination of any part of the body for diagnostic purposes by means of X-RAYS or GAMMA RAYS, recording the image on a sensitized surface (such as photographic film). Radiology, Diagnostic X-Ray,Roentgenography,X-Ray, Diagnostic,Diagnostic X-Ray,Diagnostic X-Ray Radiology,X-Ray Radiology, Diagnostic,Diagnostic X Ray,Diagnostic X Ray Radiology,Diagnostic X-Rays,Radiology, Diagnostic X Ray,X Ray Radiology, Diagnostic,X Ray, Diagnostic,X-Rays, Diagnostic
D011878 Radiotherapy The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions. Radiotherapy, Targeted,Targeted Radiotherapy,Radiation Therapy,Radiation Therapy, Targeted,Radiation Treatment,Targeted Radiation Therapy,Radiation Therapies,Radiation Therapies, Targeted,Radiation Treatments,Radiotherapies,Radiotherapies, Targeted,Targeted Radiation Therapies,Targeted Radiotherapies,Therapies, Radiation,Therapies, Targeted Radiation,Therapy, Radiation,Therapy, Targeted Radiation,Treatment, Radiation
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D006257 Head The upper part of the human body, or the front or upper part of the body of an animal, typically separated from the rest of the body by a neck, and containing the brain, mouth, and sense organs. Heads
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012886 Skull The SKELETON of the HEAD including the FACIAL BONES and the bones enclosing the BRAIN. Calvaria,Cranium,Calvarium,Skulls
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Jan-Erik Westlin, and Henry Letocha, and Åke Jakobson, and Peter Strang, and Ulla Martinsson, and Sten Nilsson
Imaging and treatment of disseminated neuroblastoma with 131I-meta-iodobenzylguanidine.
April 1987, The British journal of radiology,
Jan-Erik Westlin, and Henry Letocha, and Åke Jakobson, and Peter Strang, and Ulla Martinsson, and Sten Nilsson
Detection of neuroblastoma with 131I-meta-iodobenzylguanidine.
January 1985, Progress in clinical and biological research,
Jan-Erik Westlin, and Henry Letocha, and Åke Jakobson, and Peter Strang, and Ulla Martinsson, and Sten Nilsson
131I-meta-iodobenzylguanidine scintigraphy in patients with neuroblastoma.
January 1987, Pediatric radiology,
Jan-Erik Westlin, and Henry Letocha, and Åke Jakobson, and Peter Strang, and Ulla Martinsson, and Sten Nilsson
Toxicity from treatment of neuroblastoma with 131I-meta-iodobenzylguanidine.
January 1988, European journal of nuclear medicine,
Jan-Erik Westlin, and Henry Letocha, and Åke Jakobson, and Peter Strang, and Ulla Martinsson, and Sten Nilsson
Hypertension complicating 131I-meta-iodobenzylguanidine therapy for neuroblastoma.
April 2012, European journal of nuclear medicine and molecular imaging,
Jan-Erik Westlin, and Henry Letocha, and Åke Jakobson, and Peter Strang, and Ulla Martinsson, and Sten Nilsson
131I-meta-iodobenzylguanidine in diagnosis and treatment of neuroblastoma.
January 1988, Bulletin du cancer,
Jan-Erik Westlin, and Henry Letocha, and Åke Jakobson, and Peter Strang, and Ulla Martinsson, and Sten Nilsson
[Clinical significance of 131I meta-iodobenzylguanidine scintigraphy in neuroblastoma].
May 1988, Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica,
Jan-Erik Westlin, and Henry Letocha, and Åke Jakobson, and Peter Strang, and Ulla Martinsson, and Sten Nilsson
Treatment with meta-[131I]iodobenzylguanidine and cisplatin in stage IV neuroblastoma.
December 1995, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR),
Jan-Erik Westlin, and Henry Letocha, and Åke Jakobson, and Peter Strang, and Ulla Martinsson, and Sten Nilsson
Neuroblastoma therapy using radiolabelled [131I]meta-iodobenzylguanidine ([131I]MIBG) in combination with other agents.
August 1999, European journal of cancer (Oxford, England : 1990),
Jan-Erik Westlin, and Henry Letocha, and Åke Jakobson, and Peter Strang, and Ulla Martinsson, and Sten Nilsson
Diagnosis and treatment of neuroblastoma using 131I-meta-iodobenzylguanidine.
October 1986, Nuklearmedizin. Nuclear medicine,
Copied contents to your clipboard!